| Título : |
Overactive bladder - 18 years - Part II |
| Tipo de documento : |
documento electrónico |
| Autores : |
Juan Carlos Castaño Botero, |
| Fecha de publicación : |
2016 |
| Títulos uniformes : |
International Brazilian Journal of Urology
|
| Idioma : |
Inglés (eng) |
| Palabras clave : |
Overactive Bladder Muscarinic Antagonists Beta-adrenergic agonists Botulinum Toxin Sacral neuromodulation Urodynamics |
| Resumen : |
Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning – as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder – 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder. |
| Mención de responsabilidad : |
Jose Carlos Truzzi, Cristiano Mendes Gomes, Carlos A Bezerra, Ivan Mauricio Plata, Jose Campos, Gustavo Luis Garrido, Fernando G Almeida, Marcio Augusto Averbeck, Alexandre Fornari, Anibal Salazar, Arturo Dell'Oro, Caio Cintra, Carlos Alberto Ricetto Sacomani, Juan Pablo Tapia, Eduardo Brambila, Emilio Miguel Longo, Flavio Trigo Rocha, Francisco Coutinho, Gabriel Favre, Jose Antonio Garcia, Juan Castano, Miguel Reyes, Rodrigo Eugenio Leyton, Ruiter Silva Ferreira, Sergio Duran, Vanda Lopez, Ricardo Reges |
| Referencia : |
Int Braz J Urol. 2016 Mar-Apr;42(2):199-214. |
| DOI (Digital Object Identifier) : |
10.1590/S1677-5538.IBJU.2015.0367 |
| PMID : |
27176185 |
| Derechos de uso : |
CC BY |
| En línea : |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200199&l [...] |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3980 |
Overactive bladder - 18 years - Part II [documento electrónico] / Juan Carlos Castaño Botero, . - 2016. Obra : International Brazilian Journal of UrologyIdioma : Inglés ( eng) | Palabras clave : |
Overactive Bladder Muscarinic Antagonists Beta-adrenergic agonists Botulinum Toxin Sacral neuromodulation Urodynamics |
| Resumen : |
Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning – as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder – 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder. |
| Mención de responsabilidad : |
Jose Carlos Truzzi, Cristiano Mendes Gomes, Carlos A Bezerra, Ivan Mauricio Plata, Jose Campos, Gustavo Luis Garrido, Fernando G Almeida, Marcio Augusto Averbeck, Alexandre Fornari, Anibal Salazar, Arturo Dell'Oro, Caio Cintra, Carlos Alberto Ricetto Sacomani, Juan Pablo Tapia, Eduardo Brambila, Emilio Miguel Longo, Flavio Trigo Rocha, Francisco Coutinho, Gabriel Favre, Jose Antonio Garcia, Juan Castano, Miguel Reyes, Rodrigo Eugenio Leyton, Ruiter Silva Ferreira, Sergio Duran, Vanda Lopez, Ricardo Reges |
| Referencia : |
Int Braz J Urol. 2016 Mar-Apr;42(2):199-214. |
| DOI (Digital Object Identifier) : |
10.1590/S1677-5538.IBJU.2015.0367 |
| PMID : |
27176185 |
| Derechos de uso : |
CC BY |
| En línea : |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200199&l [...] |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3980 |
|  |
Inicio
Overactive bladder - 18 years - Part II
